Why Bristol Myers Squibb’s Sotyktu approval could reshape the oral psoriatic arthritis race
A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.
Pharma & Biotech
Pharma & Biotech
Can Takeda’s zasocitinib change the plaque psoriasis treatment ladder after Phase 3 wins?
Takeda’s zasocitinib posted strong Phase 3 psoriasis data. Read what it changes for TYK2 competition, regulation, and oral treatment strategy.
Pharma & Biotech
Bristol Myers Squibb expands Sotyktu label. Will TYK2 inhibition challenge biologics in psoriatic arthritis?
FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis. Discover what TYK2 inhibition means for autoimmune treatment and future rheumatology drugs.
Pharma & Biotech
Takeda’s zasocitinib hits key Phase 3 psoriasis goals, challenging oral and biologic rivals
Takeda Pharmaceutical Company Limited has reported positive topline results from two pivotal Phase 3 studies of its investigational drug zasocitinib (TAK-279), a once-daily oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis. The trials met all primary and secondary endpoints, with more than 50 percent of participants achieving near-complete skin clearance (PASI